Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
This interventional trial (n=100) aims to investigate the long-term maintenance effects of ketamine and esketamine on reducing suicide risk in patients with Major Depressive Disorder (MDD) and suicidal ideation (SI).
Details
This 24-week single-group treatment trial enrolls inpatients with MDD and current suicidal ideation to receive an acute course of up to eight IV ketamine infusions followed by maintenance intranasal esketamine (13 treatments). Participants are compared with matched historical controls identified from electronic medical records.
Outcomes include feasibility, tolerability, and efficacy for suicide-risk reduction and depressive symptoms, as well as predictors of response; assessments include seven long visits, five short visits, and daily surveys.